CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced positive topline data from the completed Part A safety lead-in of the Company’s THIO-101 Phase 2 go-to-market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results